DUBLIN, April 17, 2023 /PRNewswire/ -- Endo International
plc (OTC: ENDPQ) announced today that its Par Sterile Products
business has begun shipping argatroban injection to healthcare
providers through Premier's Premier ProRx® private-label
program, a guaranteed supply for hospitals and health systems.
Argatroban is on FDA's essential medications list and has
experienced intermittent supply issues in the broader market.
"We're pleased to join Premier in helping to address industry
drug supply and serving as a guaranteed supplier of argatroban,
manufactured in our Rochester,
Michigan facility," said Scott
Sims, Senior Vice President and General Manager, Injectable
Solutions & Generics at Endo. "We're proud to now provide a
third product through the reliable Premier ProRx® supply
channel."
Endo also supplies its Adrenalin® (epinephrine
injection, USP), Vasostrict® (vasopressin injection,
USP) and fluphenazine decanoate injection, USP products to
Premier's hospital customers through the Premier ProRx®
private-label program.
About Endo
Endo (OTC: ENDPQ) is a specialty
pharmaceutical company committed to helping everyone we serve live
their best life through the delivery of quality, life-enhancing
therapies. Our decades of proven success come from passionate team
members around the globe collaborating to bring treatments forward.
Together, we boldly transform insights into treatments benefiting
those who need them, when they need them. Learn more at
www.endo.com or connect with us on LinkedIn.
About Par Pharmaceutical
Par Pharmaceutical develops,
manufactures and markets innovative and cost-effective generic
pharmaceutical and branded injectable products that help improve
patients' lives. Par, among the top leaders in the U.S. generics
industry, possesses an expanding portfolio that includes sterile
injectables, alternative dosage forms and other differentiated
products. Par Pharmaceutical is an Endo company. Learn more at
www.parpharm.com.
Cautionary Note Regarding Forward-Looking
Statements
Certain information in this press release may be
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and any applicable
Canadian securities legislation including, but not limited to, the
statements by Mr. Sims and any statements relating to product
launch, shipment, sales, supply or distribution, and any statements
that refer to expected, estimated or anticipated future results or
that do not relate solely to historical facts. Statements including
words or phrases such as "believe," "expect," "anticipate,"
"intend," "estimate," "plan," "will," "may," "look forward,"
"intend," "guidance," "future," "potential" or similar expressions
are forward-looking statements. All forward-looking statements in
this communication reflect the Company's current views as of the
date of this communication about its plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to it and on assumptions it has
made. Actual results may differ materially and adversely from
current expectations based on a number of factors, including, among
other things, the outcome of the Company's contingency planning and
restructuring activities; the timing, impact or results of any
pending or future litigation, investigations, proceedings or
claims, including opioid, tax and antitrust related matters; any
actual or contingent liabilities; settlement discussions or
negotiations; the Company's liquidity, financial performance, cash
position and operations; the risks and uncertainties associated
with chapter 11 proceedings; the time, terms and ability to confirm
a sale of the Company's businesses under Section 363 of the U.S.
Bankruptcy Code; the risk that the Company's chapter 11 cases may
be converted to cases under chapter 7 of the Bankruptcy Code; the
adequacy of the capital resources of the Company's businesses and
the difficulty in forecasting the liquidity requirements of the
operations of the Company's businesses; the unpredictability of the
Company's financial results; the Company's ability to discharge
claims in chapter 11 proceedings; negotiations with the holders of
the Company's indebtedness and its trade creditors and other
significant creditors; the risks and uncertainties with performing
under the terms of the restructuring support agreement and any
other arrangement with lenders or creditors while in chapter 11
proceedings; the performance, including the approval, introduction,
and consumer and physician acceptance of new products and the
continuing acceptance of currently marketed products; and the
Company's ability to obtain and successfully manufacture, maintain
and distribute a sufficient supply of products to meet market
demand in a timely manner. The Company expressly disclaims any
intent or obligation to update these forward-looking statements,
except as required to do so by law.
Additional information concerning risk factors, including those
referenced above, can be found in press releases issued by the
Company, as well as the Company's public periodic filings with the
U.S. Securities and Exchange Commission and with securities
regulators in Canada, including
the discussion under the heading "Risk Factors" in the Company's
most recent Annual Report on Form 10-K and any subsequent Quarterly
Reports on Form 10-Q or other filings with the U.S. Securities and
Exchange Commission.
Logo -
https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/endo-announces-launch-of-argatroban-injection-through-premiers-prorx-private-label-program-301798382.html
